---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-020108"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:41:25.397322+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports Q4 net loss $50.2M ($0.47/sh); cash $530M; key trial readouts in 2026

## Summary
- Net loss for Q4 2025 was $50.2M ($0.47/sh) vs $40.7M ($0.39/sh) in prior quarter; no revenue.
- Cash, cash equivalents and marketable securities total $530.1M as of Dec 31, 2025.
- GRAND CANYON top-line results for sevasemten in Becker expected Q4 2026; NDA submission H1 2027.
- CIRRUS-HCM Part D 12-week data for EDG-7500 in HCM expected H1 2026; Phase 3 start H2 2026.
- EDG-15400 Phase 1 healthy adult data H1 2026; Phase 2 in HFpEF planned H2 2026.

## SEC filing metadata
- accession: 0001104659-26-020108
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/0001104659-26-020108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/tm266859d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-020108
- JSON: https://secwatch.observer/filing/0001104659-26-020108.json
- Plain text: https://secwatch.observer/filing/0001104659-26-020108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.